# First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Luis Paz‐Ares,Suresh S. Ramalingam,Tudor–Eliade Ciuleanu,Jong-Seok Lee,László Urbán,Reyes Bernabe Caro,Keunchil Park,Hiroshi Sakai,Yuichiro Ohe,Makoto Nishio,Clarisse Audigier-Valette,Jacobus A. Burgers,Adam Płużański,Randeep Sangha,Carlos Gallardo,Masayuki Takeda,Helena Linardou,Lorena Lupinacci,Ki Hyeong Lee,Claudia Caserta,Mariano Provencio,Enric Carcereny,Gregory A. Otterson,Michael Schenker,Bogdan Żurawski,Aurelia Alexandru,A. Vergnenègre,Judith Raimbourg,Kynan Feeney,Sang‐We Kim,Hossein Borghaei,Kenneth J. O’Byrne,Matthew D. Hellmann,Arteid Memaj,Faith E. Nathan,Judith Bushong,Phuong Tran,Julie R. Brahmer,Martin Reck |
| Citations | 324 |
| DOI | 10.1016/j.jtho.2021.09.010 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jtho.2021.09.010 |
| OpenAlex ID | https://openalex.org/W3207786785 |
| PMID | 34648948 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Matthew D. Hellmann](https://scholariq.org/researchers/matthew-d-hellmann/)
- [Keunchil Park](https://scholariq.org/researchers/keunchil-park/)
- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)
- [Judith Raimbourg](https://scholariq.org/researchers/judith-raimbourg/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.